Crescent Biopharma develops oncology therapeutics that combine multiple modalities to improve efficacy and tolerability in solid tumors. Its lead program, CR‑001, is a tetravalent PD‑1 × VEGF bispecific antibody, complemented by ADC candidates CR‑002 and CR‑003 that deliver topoisomerase‑1 inhibitor payloads to cancer cells. The pipeline is designed for use as monotherapy or in combination, targeting validated checkpoints and angiogenesis pathways for advanced cancer treatment.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with solid tumors often have limited treatment options because existing therapies may lack efficacy, cause significant toxicity, or fail to address multiple disease mechanisms simultaneously.
Solution
Crescent Biopharma develops a portfolio of oncology therapeutics that combine distinct modalities to improve anti‑tumor activity while maintaining tolerability. Its lead candidate, CR‑001, is a tetravalent PD‑1 × VEGF bispecific antibody that simultaneously blocks immune checkpoint signaling and tumor angiogenesis, leveraging cooperative binding to enhance efficacy. The company also advances antibody‑drug conjugates (ADCs) such as CR‑002 (PD‑L1‑targeted) and CR‑003 (integrin‑β6‑targeted) that deliver topoisomerase‑1 inhibitor payloads directly to cancer cells. By pairing the bispecific immunotherapy with these ADCs, Crescent aims to create synergistic regimens that can be used as monotherapy or in combination across multiple solid‑tumor indications. The pipeline is built on validated targets and established biology to accelerate clinical development and increase the probability of regulatory success.
Target Audience
Primary customers are pharmaceutical partners and oncology clinical development programs seeking novel immuno‑oncology and ADC candidates for solid‑tumor treatment, as well as healthcare providers treating patients with advanced cancers.
Features
- Tetravalent PD‑1 × VEGF bispecific antibody (CR‑001) with cooperative pharmacology that enhances checkpoint inhibition and VEGF blockade within the tumor microenvironment
- ADC platforms (CR‑002 and CR‑003) delivering a topoisomerase‑1 inhibitor payload via high‑affinity antibodies against PD‑L1 or integrin‑β6, respectively
- Proprietary K‑thiol irreversible conjugation technology for stable linker chemistry and precise payload release
- Designed for flexible use as standalone agents or in combination with CR‑001 to exploit synergistic anti‑tumor mechanisms
- Focus on solid‑tumor indications with global development plans, including exclusive partnership for Greater China commercialization